Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.64 |
| ▸ | CLPP | Q16740 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845846 | 0.80 | FKBP1A (0.46) | GRM5 | |
| SCHEMBL5847498 | 0.79 | FKBP1A (0.43) | — | |
| SCHEMBL7370584 | 0.77 | GRM5 (0.54) | GRM5CLPPSPHK2SPHK1 | |
| SCHEMBL15494262 | 0.74 | ALDH1A1 (0.52) | — | |
| SCHEMBL1685056 | 0.74 | ALDH1A1 (0.52) | — | |
| SCHEMBL1951891 | 0.74 | GRM5 (0.55) | GRM5SPHK2SPHK1 | |
| SCHEMBL1951889 | 0.74 | GRM5 (0.55) | GRM5SPHK2SPHK1 | |
| SCHEMBL7995095 | 0.73 | FKBP1A (0.57) | — | |
| SCHEMBL7995090 | 0.73 | FKBP1A (0.57) | — | |
| SCHEMBL19033747 | 0.73 | HCRTR1 (0.59) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135370-B1 | CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES OF N-HETEROCYCLIC COMPOUNDS | GUILFORD PHARM INC (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030186961-A1 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GUILFORD PHARMACEUTICALS | 2003-10-02 | — | — | US | claimed |
| US-7153883-B2 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GPI NIL HOLDINGS INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1135370-B1 | CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES OF N-HETEROCYCLIC COMPOUNDS | GUILFORD PHARM INC (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030186961-A1 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GUILFORD PHARMACEUTICALS | 2003-10-02 | — | — | US | disclosed |
| US-6331537-B1 | TREATING NEUROLOGICAL DISORDERS IN ANIMALS | GPI NIL HOLDINGS, INC. | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186961-A1 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | BDNF, NGF, HCAR2 | GRM5 838/4885CLPP 4863/4885SPHK2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.